Owyang, Stephanie
Jastrzebska-Perfect, Patricia
Scott, Michael
Traverso, Giovanni
Article History
First Online: 28 February 2023
Competing interests
: G.T. receives current and prior funding from Novo Nordisk. Personal financial interests include equity/stock (Lyndra Therapeutics, Suono Bio, Vivtex, Celero Systems, Syntis Bio), board of directors member and/or consultant (Lyndra Therapeutics, Novo Nordisk, Suono Bio, Vivtex, Celero Systems, Syntis Bio) and royalties (past and potentially in the future) from licensed and/or optioned intellectual property (Lyndra Therapeutics, Novo Nordisk, Suono Bio, Vivtex, Celero Systems, Syntis Bio, Johns Hopkins, MIT, Mass General Brigham Innovation). Complete details of all relationships for profit and not-for-profit for G.T. can be found in the InternalRef removed. M.S. is an employee of Novo Nordisk. The remaining authors declare no competing interests.